Clinical study of standard CEOP regimen in the treatment of elderly non-Hodgkin' s lymphoma patients

VernacularTitle:标准剂量CEOP方案治疗老年非霍奇金淋巴瘤患者的临床观察
Author: Biyun CHEN ; Ying XIE ; Shuang QU
Publication Type:Journal Article
Keywords: Lymphoma,non-Hodgkin's; Antineoplastic combined chemotherapy protocols
From: Journal of Leukemia & Lymphoma 2012;21(12):739-741
CountryChina
Language:Chinese
Abstract: Objective To study the efficacy and toxicity of standard CEOP regimen in elderly patients with non-Hodgkin's lymphoma (NHL).Methods The study included 34 previously untreated patients,age 60 to 80 years old,with NHL,through July 2009 to December 2011.The patients with T-cell lyphoma received four to eight cycles of CEOP (cyclophosphamide 750 mg/m2 d1,epirubicin hydrochloride 60-75 mg/m2 d1,vincristine 2mg d1,and dexamethasone 10-15 mg d1-5) every 3-4 weeks.Otherwise,the patient with B-cell lymphoma received R-CEOP,rituximab (375 mg/m2) was administered one day before CEOP.All the patients' clinical materials were collected and used to annalyze the efficacy and toxicity of the CEOP±R regimen.Results Among these 34 NHL patients,17 cases reached CR,9 cases reached PR,3 cases remained SD,and 5 cases appeared PD.The total response rate was 76.5 ％(26/34).The major toxicity was bone marrow restraint.The rate of leukocyte decline with Ⅲ-Ⅳ degree was 71.4 ％ (24/34).Conclusion Using the standard regimen of CEOP leads to satisfied efficacy of elderly patients with NHL,and the toxcity is tolerant.